Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$0.91 USD
-0.01 (-0.90%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $0.91 0.00 (0.39%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
Seres Therapeutics, Inc. [MCRB]
Reports for Purchase
Showing records 21 - 36 ( 36 total )
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bold Action Culminates in a Positive SER-109 Phase 3 Readout; Reiterate Buy and Raising PT to $41
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fortune Favors the Bold as SER-109 Accelerates its Advance; Reiterate Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Look for Readouts in 2020 to Reaffirm the Safety of Seres.
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
High Priority Programs Continue Their Advance to Important Catalysts in 2020; Reiterate Buy Rating and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Programs Make Solid 2Q19 Progress but are Flying Under the Radar; Reiterate Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Results Reflect Headwinds to ECOSPOR III Persist but Costs Streamlined; Reiterating Buy and Adjusting PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AstraZeneca Collaboration Further Confirms Seres? Leadership in Potential Applications of the Microbiome in Oncology
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lowering our PT to $13 but Remaining Positive That ECOSPOR III Prevails Against Headwinds in Patient Enrollment
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Healthy Dose to the Gut Microbiome; Assuming Coverage With a Buy and $16 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SER-287 Phase 1B Trial Results in Ulcerative Colitis Patients Expected in 2H17; PT Raised to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Disappointing SER-109 Phase 2 Results; Reducing Price Target to $15 from $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Good Microbes Can Conquer Disease; Assuming Coverage With a $50 12-Month Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Microbiome Restoration Pills Make Headway in CDI and UC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Restoring Order to Unruly Microbiota; Initiating with a Buy Rating and $55 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M